Your marketing claims meet industry standards. Your labeling passed internal review. Yet you’ve received an FDA Warning Letter, an FTC demand letter, or worse – notification that the Department of Justice is investigating potential criminal misbranding charges.
I know this because enforcement against food, supplement, and consumer product advertising has intensified dramatically in 2025-2026. FDA issued over 100 cease-and-desist letters in September 2025 alone following a presidential directive to crack down on “deceptive” advertising. FTC coordination with FDA has produced enforcement actions targeting health claims, fake reviews, and “all natural” representations that companies believed were defensible.
This article examines the defenses actually available when facing false advertising or misbranding allegations, why most companies wait too long to assert them, and what experienced regulatory defense counsel does differently in the critical window between initial enforcement contact and formal charges.
The Enforcement Reality Facing Food and Supplement Companies
The regulatory environment for food and dietary supplement advertising has transformed into a multi-agency enforcement system where every marketing channel faces scrutiny.
FDA’s Human Foods Program became fully operational in mid-2026, centralizing decision-making and reducing the time between inspectional findings and follow-up enforcement action. The reorganization means greater consistency in how similar issues are treated – but also shorter response windows and faster escalation from Warning Letters to formal enforcement proceedings.
FTC enforcement has expanded beyond traditional advertising into influencer content, social media endorsements, and third-party marketplace listings. In July 2025, FTC issued warning letters to Amazon and Walmart regarding third-party seller origin claims. The agency’s fake review crackdown in late 2025 warned that violations carry civil penalties up to $53,088 per violation – amounts that quickly multiply across large campaigns.
Department of Justice involvement has increased as well. FDA Commissioner Makary stated the agency will return to a 1990s paradigm of issuing hundreds of enforcement letters annually. When those letters identify potential criminal violations – particularly intentional misbranding – DOJ’s Criminal Division increasingly pursues prosecutions against both companies and individuals.
State attorneys general have also activated, pursuing deceptive advertising claims under state law, often piggybacking on federal enforcement while adding state-specific penalties. Finally, private litigation follows agency action like clockwork. Class action plaintiffs routinely cite FDA Warning Letters and FTC complaints as evidence that companies knew their claims were false or misleading.
Common Defense Strategies in False Advertising Cases
When companies face enforcement actions, several defense approaches exist – though their viability depends critically on the specific allegations, the strength of available evidence, and how early counsel engages.
Substantiation Defense
The most fundamental defense asserts that the company possesses adequate substantiation for its claims. Under FTC law, advertisers must have competent and reliable scientific evidence supporting objective product claims before disseminating advertisements. For health-related claims, this typically means randomized controlled clinical trials, systematic reviews, or other research meeting accepted scientific standards in the relevant field.
The challenge is that “adequate” substantiation is determined by what experts in the field believe is reasonable – not what the company’s marketing team considered sufficient. A single pilot study, animal research, or in vitro data rarely satisfies this standard for claims about human health effects.
Companies asserting substantiation defenses must produce their evidence quickly and comprehensively. Holding back studies while testing agency receptiveness or producing documents incrementally signals weakness. Experienced defense counsel organizes all substantiation materials into a coherent scientific narrative demonstrating that the claims were reasonable when made.
Claim Interpretation Defense
Many enforcement actions hinge on what claims the advertising actually communicates to reasonable consumers. Companies may argue that agencies misinterpret the message or read implications into advertising that consumers would not reasonably draw.
This defense works best when the challenged statements are literally true but agencies allege implied false claims. For example, a statement that a supplement “supports immune function” might be literally accurate as a structure-function claim, but agencies may argue it implies the product prevents disease – a drug claim requiring FDA approval.
Consumer perception evidence can support claim interpretation defenses. If survey data shows that consumers do not interpret advertising the way agencies allege, that evidence may persuade agencies to narrow their theories. However, companies rarely commission such surveys before enforcement begins.
Compliance with FDA Regulations Defense
Companies sometimes argue that their claims comply with FDA’s food labeling regulations and therefore should not be subject to FTC enforcement. This defense has merit in limited circumstances because FTC has stated it is unlikely to take action regarding nutrient content and health claims that comply with FDA regulations.
The problem is that FDA approval for labeling claims does not automatically immunize advertising claims. FTC applies broader deception principles to advertising that can capture misleading implications even when literal statements meet FDA standards. Additionally, many enforcement actions target claims that do not comply with FDA regulations at all.
Disclosure and Context Defense
Companies may argue that their advertising included adequate disclosures qualifying the challenged claims or that claims must be evaluated in full context rather than in isolation.
This defense requires that disclosures actually reached consumers. Fine print disclaimers, hyperlinked terms and conditions, or qualifications buried at the end of video advertisements generally do not cure misleading primary claims. FTC and FDA expect disclosures to be clear, conspicuous, and placed where consumers will see them before making purchase decisions.
Context can matter when agencies excerpt statements from longer materials in ways that change meaning. However, agencies typically cite statements appearing on product packaging, website landing pages, or social media posts where consumers see claims in isolation from qualifying information.
First Amendment Commercial Speech Defense
Companies facing enforcement sometimes raise First Amendment protections for commercial speech. While the Supreme Court affords commercial speech constitutional protection, that protection operates at a lower level than political or artistic speech.
First Amendment defenses rarely succeed against enforcement actions targeting demonstrably false claims. They have greater potential when agencies seek to restrict truthful, non-misleading speech or impose disclosure requirements so burdensome they effectively prohibit communication.
Why Most Defenses Fail: The Critical Mistakes Companies Make
Most false advertising and misbranding defenses fail not because the legal theories lack merit but because companies make strategic and tactical errors that undermine their positions.
The first mistake is delay. When companies receive FDA Warning Letters or FTC demand letters, internal teams often spend weeks debating whether to respond. This delay costs critical preparation time. Agencies interpret non-response or slow response as admission that the violations are indefensible.
The second mistake is incomplete or poorly organized substantiation. Companies scramble to locate supporting studies and produce documents piecemeal, mixing relevant and irrelevant materials. Agencies reviewing chaotic substantiation files conclude the company lacks adequate support.
The third mistake is making admissions in initial responses. Company personnel write letters acknowledging that claims “may have been unclear” or that substantiation “could have been stronger.” These admissions become evidence in subsequent enforcement proceedings and private litigation.
The fourth mistake is continuing violative marketing while under investigation. Companies receiving Warning Letters sometimes make minimal changes while maintaining the core challenged claims. This demonstrates to agencies that the company does not take the violations seriously.
The fifth mistake is providing access to personnel without preparation. Companies allow agency interviews hoping to demonstrate transparency. Unprepared personnel make inconsistent statements, contradict prior positions, or acknowledge facts undermining potential defenses.
When Criminal Exposure Exists: Misbranding as More Than Regulatory Violation
Most companies think of false advertising enforcement as civil regulatory action. They do not appreciate the criminal exposure that certain violations create.
The Federal Food, Drug, and Cosmetic Act makes misbranding a criminal offense. Section 303 establishes that violations are misdemeanors punishable by imprisonment up to one year and fines, with felony enhancements for repeat offenders or violations committed with intent to defraud or mislead.
Criminal exposure increases dramatically when evidence shows that companies knew their claims were false or continued making challenged claims after receiving FDA Warning Letters. Emails discussing whether claims can be “stretched,” internal memos questioning substantiation, or decisions to ignore scientific advice create evidence of intent that transforms civil violations into criminal conduct.
Individual liability also expands in criminal cases. Criminal misbranding charges can reach executives, marketing directors, and other personnel responsible for violative conduct. The “responsible corporate officer” doctrine allows prosecution of individuals in supervisory positions even without direct participation in violations.
When criminal exposure exists, defense strategy changes fundamentally. Companies must evaluate whether cooperation benefits outweigh self-incrimination risks. Personnel need counsel representing their individual interests separate from corporate counsel.
The Role of Experienced Regulatory Defense Counsel
The difference between successful and unsuccessful defense of false advertising allegations usually comes down to whether companies engage experienced regulatory defense counsel early enough to matter.
Experienced counsel starts by conducting rapid internal investigation to understand exactly what claims the company made, what substantiation exists, and what communications about those claims might become relevant. This investigation happens under attorney-client privilege, protecting the information from disclosure while allowing counsel to assess defense strength.
Counsel then develops a response strategy calibrated to the specific allegations and the agency’s enforcement posture. For some cases, comprehensive substantiation submissions may achieve resolution. For others, acknowledgment of specific issues combined with immediate corrective action and enhanced compliance procedures may satisfy agency concerns.
Counsel manages all agency communications to ensure consistency, prevent admissions, and maintain strategic positioning. This includes drafting written responses, preparing personnel for interviews, and conducting negotiations with agency staff.
Experienced counsel also recognizes when defending current claims becomes secondary to protecting the company from expanded investigation. Agencies sometimes identify violations beyond the initial allegations during investigation. Counsel works to keep agency focus on specific issues rather than allowing broad-ranging examination of all marketing practices.
Responding to Warning Letters: The Critical First Step
FDA Warning Letters and FTC demand letters serve as the first formal enforcement contact for most companies. How companies respond determines whether matters resolve quickly or escalate into formal proceedings.
The immediate priority is stopping the clock. Warning Letters typically provide 15 business days to respond with specific corrective actions. Companies that miss deadlines or request extensions without providing interim responses signal to agencies that they are not taking violations seriously.
Responses must be specific. Agencies reject vague commitments to “review marketing materials” or “enhance compliance programs.” Effective responses identify each alleged violation, explain either why it does not violate law or how it will be corrected, provide timelines for corrective action, and describe verification measures.
Companies must also address the root causes that led to violations. Agencies want to know that corrections are permanent rather than superficial. This means explaining procedural changes, enhanced review requirements, personnel training, or other systemic improvements preventing recurrence.
For allegations that companies believe are incorrect, responses must explain why with specificity backed by evidence. Conclusory statements that “the company disagrees” accomplish nothing. Responses must cite applicable regulations, provide substantiation materials, or explain scientific bases for claims.
Why Companies Cannot Afford to Wait
The single most dangerous assumption companies make when facing false advertising allegations is that they have time to evaluate options and decide how to respond. The reality is that delay costs companies viable defenses and increases exposure.
From the moment companies receive enforcement letters, the clock is running on multiple critical deadlines. FDA Warning Letters expect responses within 15 business days. Missing these deadlines signals non-compliance and triggers escalation.
But the deadline problem goes deeper. Evidence supporting potential defenses becomes stale with each passing day. Personnel who made claims move to other positions. Substantiation files get archived or lost. Communications about claim development that might demonstrate good faith disappear.
Meanwhile, agencies are not waiting. FDA and FTC continue investigating, expanding the scope of inquiry, and building enforcement cases. Companies that delay response while agencies proceed with investigation find themselves defending against broader allegations with less time to prepare.
Criminal exposure also increases with delay. When companies continue making challenged claims after receiving Warning Letters, they demonstrate knowing and willful violation of law. This transforms potential civil misbranding into criminal conduct.
Perhaps most critically, companies that delay engaging counsel often make irreversible strategic errors. They respond to agencies without understanding the implications of their statements. They provide documents without evaluating privilege protections. By the time they retain experienced counsel, they have foreclosed defense options and strengthened the case against them.
The 2026 Enforcement Environment: Heightened Risk and Shorter Windows
The enforcement environment facing food and supplement companies has fundamentally changed in 2025-2026, creating risks that demand immediate response when allegations arise.
FDA’s September 2025 issuance of over 100 enforcement letters in a single month represents a new enforcement paradigm. Commissioner Makary’s commitment to return to 1990s-level enforcement means hundreds of additional letters annually.
The shift from FDA’s Office of Prescription Drug Promotion issuing enforcement letters to CDER and CBER Directors signing them signals elevated seriousness. These are not routine compliance matters delegated to staff reviewers. They are high-priority enforcement actions receiving senior leadership attention.
FTC’s enhanced focus on influencer marketing, fake reviews, and social media advertising means that companies face exposure through marketing channels they may not directly control. When influencers make unsupported claims about products, FTC holds companies responsible regardless of whether internal compliance personnel approved those specific statements.
State enforcement has activated as well, with attorneys general pursuing deceptive advertising under state consumer protection statutes that often provide stronger remedies than federal law. Companies facing federal enforcement should anticipate state investigations following the same theories.
What Companies Should Do Now
Companies marketing food, dietary supplements, or consumer products with health-related claims should take immediate action regardless of whether they currently face enforcement.
First, conduct comprehensive advertising audit. Review all marketing materials identifying any claims that might lack adequate substantiation or violate FDA or FTC requirements.
Second, evaluate substantiation for every objective product claim. Gather the studies, research, and expert assessments supporting claims. Have qualified scientific advisors review whether evidence meets accepted standards in relevant fields.
Third, implement enhanced review procedures for new marketing materials. Require scientific, regulatory, and legal review before any claim is published.
Fourth, monitor enforcement trends affecting your product category. Track FDA Warning Letters, FTC complaints, and class action filings. When agencies identify violations at competitor companies, evaluate whether your marketing practices create similar exposure.
Fifth, prepare response protocols for enforcement contact. Identify experienced regulatory defense counsel so that when enforcement occurs, you can engage counsel immediately rather than losing days searching for appropriate representation.
Finally, if you have received FDA Warning Letters, FTC demand letters, or become aware of pending agency investigation, engage experienced regulatory defense counsel immediately. Do not attempt to handle these matters through internal resources or general corporate counsel unfamiliar with FDA and FTC enforcement practices.
False Advertising Defense Services with OFW Law
False advertising and misbranding allegations represent serious legal exposure that can result in regulatory sanctions, criminal prosecution, civil litigation, and permanent business damage. The defenses available to companies depend critically on substantiation quality, response timing, and strategic positioning.
The 2025-2026 enforcement environment has intensified dramatically following presidential directives, FDA reorganization, and increased coordination between agencies. Companies that marketed products successfully for years under prior enforcement priorities now face scrutiny for practices that were previously unchallenged.
Delay in responding to enforcement actions is the most dangerous mistake companies make. Every day without appropriate response costs viable defenses, increases exposure, and reduces resolution options. Companies that wait to engage experienced counsel typically find that matters have escalated beyond the point where favorable resolution is achievable.
If your company has received enforcement correspondence, become aware of agency investigation, or markets products with health-related claims in this heightened enforcement environment, contact our office immediately. We defend food and supplement companies in FDA and FTC enforcement proceedings, Warning Letter responses, and criminal misbranding investigations. The difference between successful defense and devastating outcome often comes down to whether companies engage experienced counsel early enough to matter.
